News Industry News Medtronic Announces Renal Denervation Pivotal Trial for the Treatment of Hypertension April 09, 2018
News Daily News Pills or Even Tea More Palatable Than Exercise for the Treatment of Hypertension, US Adults Say Michael O'Riordan April 09, 2018
News Conference News ACC 2018 High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab Michael O'Riordan March 20, 2018
News Conference News ACC 2018 Mixing Haircuts and Hypertension Rx a ‘Home Run’ for Blood Pressure Control Todd Neale March 12, 2018
News Conference News ACC 2018 Reducing Co-payments for P2Y12 Inhibitors Upped Ticagrelor Use but Didn’t Budge MACE: ARTEMIS Caitlin E. Cox March 11, 2018
News Conference News ACC 2018 ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit Michael O'Riordan March 10, 2018
News Daily News Healthcare Spending on the Rise for Working-Age Adults With Hypertension Todd Neale March 07, 2018
News Conference News ISET 2018 ‘Bioconvertible’ IVC Filter Does Its Job Then Moves On: SENTRY Trial Caitlin E. Cox February 15, 2018
News Daily News Nonstatin Use and Expenditures Are Up Despite the Dearth of Evidence Supporting Efficacy Yael L. Maxwell January 29, 2018
News Conference News ISC 2018 Highly Anticipated COMPASS Results Boost Aspiration for Acute Ischemic Stroke Todd Neale January 26, 2018
News Daily News Attacking DVT With Drug-Device Combo Does Not Reduce Postthrombotic Syndrome Todd Neale December 08, 2017
News Conference News AHA 2017 ‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18 Michael O'Riordan November 15, 2017
News Conference News AHA 2017 Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear Todd Neale November 14, 2017
News Conference News AHA 2017 Low High-Sensitivity Troponin I Cutoff May Allow Discharge From ED for Many Todd Neale November 11, 2017
News Conference News AHA 2017 AHA 2017: New Hypertension Guidelines, COMPASS Costs, Dual Drug Dilemmas, and More Shelley Wood November 09, 2017
News Conference News TCT 2017 FAME 2 at 3 Years: Outcomes, Symptoms Better With PCI vs OMT in Stable CAD, at Similar Cost L.A. McKeown November 02, 2017
News Conference News TCT 2017 Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery Yael L. Maxwell October 31, 2017
News Conference News TCT 2017 Help for Clinicians Whose Patients Need to Switch P2Y12 Inhibitors Todd Neale October 30, 2017
News Daily News PCSK9 Inhibitors: More Data Show Disappointing Approval Rates of Prescriptions by Payers Yael L. Maxwell October 30, 2017
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for October 2017 Shelley Wood October 29, 2017